Sign in
Not yet taking people in United StatesPhase 4

Clinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match

Key facts

Who runs it
Dr. Daniel H. Chang, MD
Where
Bakersfield, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
68 people, planned
Started
1 Oct 2026
Expected to end
1 Mar 2027
Type of study
Interventional, 2 groups
Treatments tested
  • TECNIS PureSee IOL (Model DEN00V/DET150)
  • TECNIS Odyssey IOL (Model DRN00V/DRT150)
Record updated
6 October 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Minimum 22 years of age
  • Bilateral cataracts for which posterior chamber IOL implantation has been planned
  • Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with a glare source or 20/40 Snellen or worse without a glare source
  • Potential for postoperative BCDVA of 20/30 Snellen or better
  • Corneal astigmatism:
  • Normal corneal topography
  • Preoperative corneal astigmatism range from 0 D - 2.0 D
  • Expected post-operative astigmatism < 1.0 D
  • Clear intraocular media other than cataract in each eye
  • Availability, willingness, and sufficient cognitive awareness to comply with examination procedures
  • Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
  • Ability to understand and respond to a questionnaire in English

Who cannot take part

  • Prior corneal refractive surgery (SMILE, LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcomes or increase risk to the subject, are acceptable
  • Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
  • Use of systemic or ocular medications that may affect vision
  • Prior, current, or anticipated use during the course of the 3 month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
  • may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
  • may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
  • Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
  • History of PMMA or RGP contact lens wear within the last 5 years
  • Subject with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
  • Poorly controlled diabetes
  • Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable
  • Known ocular disease or pathology that, in the opinion of the investigator,
  • Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
  • Requiring an intraocular lens power outside the available range of power
  • Any clinically significant pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)
  • Irregular corneal astigmatism
  • Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
  • Corneal abnormalities such as stromal, epithelial, or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
  • Inability to achieve keratometric stability for soft contact lens wearers
  • may affect visual acuity

Where in United States

  • Empire Eye and Laser CenterBakersfield, United StatesContact: Brittany Camirand, BSc, CCRC, COANot yet recruiting

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the binocular clinical endpoints of distance, intermediate, and near vision and patient reported outcomes utilizing mini-monovision versus mix-match approaches for the correction of presbyopia with intraocular lenses.

The 2 groups in the trial

  • Mini-Monovision (TECNIS PureSee)Treatment being tested

    Participants will receive bilateral TECNIS PureSee IOLs (Model DEN00V/DET150), with the non-dominant eye targeted for a "second minus" near aim to achieve mini-monovision.

    Treatment: TECNIS PureSee IOL (Model DEN00V/DET150)

  • Mix-Match (TECNIS PureSee + TECNIS Odyssey)Treatment being tested

    Participants will receive a TECNIS PureSee IOL (Model DEN00V/DET150) in their dominant eye and a TECNIS Odyssey IOL (Model DRN00V/DRT150) in their non-dominant eye.

    Treatment: TECNIS PureSee IOL (Model DEN00V/DET150) and TECNIS Odyssey IOL (Model DRN00V/DRT150)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 October 2026